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Pleural effusion (PE), excess fluid in the pleural space, is often observed in lung cancer patients and also forms due to
many benign ailments. Classifying it quickly is critical, but this remains an analytical challenge often lengthening the
diagnosis process or exposing patients to unnecessary risky invasive procedures.We tested the analysis of PE using a
multiplexed cytokeratin (CK) panel with targeted mass spectrometry–based quantitation for its rapid classification. CK
markers are often assessed in pathological examinations for cancer diagnosis and guiding treatment course. We
developed methods to simultaneously quantify 33 CKs in PE using peptide standards for increased analytical
specificity and a simple CK enrichment method to detect their low amounts. Analyzing 121 PEs associated with a
variety of lung cancers and noncancerous causes, we show that abundance levels of 10 CKs can be related to PE
etiology. CK-6, CK-7, CK-8, CK-18, and CK-19 were found at significantly higher levels in cancer-related PEs.
Additionally, elevated levels of vimentin and actin differentiated PEs associated with bacterial infections. A classifier
algorithm effectively grouped PEs into cancer-related or benign PEs with 81% sensitivity and 79% specificity. A set of
undiagnosed PEs showed that ourmethod has potential to shorten PE diagnosis time. For the first time, we show that
a cancer-relevant panel of simple-epithelial CKmarkers currently used in clinical assessment can also be quantitated in
PEs. Additionally, while requiring less invasive sampling, ourmethodology demonstrated a significant ability to identify
cancer-related PEs in clinical samples and thus could improve patient care in the future.
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Lung cancer is the most common cancer worldwide in terms of
incidence and mortality [1]. It is classified into small cell lung cancer
(SCLC) and non–small cell lung cancer (NSCLC, 85% of all cases),
with NSCLC further subtyped most commonly into adenocarcinoma
(ADC) and squamous cell carcinoma (SCC). A definite diagnosis in
most cases occurs after highly invasive procedures that allow for visual
assessment of the thoracic cavity and/or sampling of the tumor and
histopathological analysis [2]. The hope is that an in-depth analysis of
the pleural effusion (PE), the fluid that accumulates in the pleural
space and is developed by 50% of lung cancer patients, could bring
diagnostically valuable information and, at some level, replace the
invasive procedures if they are unnecessary [3]. The less invasive
procedure for its required removal (thoracentesis) and the proximity
to the tumor make PE an ideal source of potential biomarkers, as has
already been demonstrated [4]. PEs also develops due to benignailments and can usually be separated into transudates (often caused
by heart, renal, and liver failures) or exudates (caused often by
infections, malignancy, and lung cancer) based on standard clinical
Table 1. (A) Makeup of the PE Sample Set; (B) Characteristics of the Patients’ Population
A B
Cancer 42 Number of
Patients
Median of
Age (yr)Lung cancer 35
NSCLC 28 Cancer 68
ADC 15 Female 13
SCC 10 Male 29
SCLC 7 Benign 67
Nonlung cancer 7 Female 5
Male 42
Benign 47 Unknown 64
Bacterial 30 Female 10
Empyema 24 Male 22
Tuberculosis 6
Transudates 14
Posttraumatic 3
Unknown 32
400 Profiles in Cancer-Related Pleural Effusions Domanski et al. Neoplasia Vol. 18, No. 7, 2016laboratory parameters [3]. Determining the exudate etiology can be
difficult. The diagnosis of a malignant PE (metastasis to the pleural
cavity) requires a positive result of cytology in the sediment.
Unfortunately, the sensitivity of this test is low, often below 60%
[5]. Hence, patients with a negative cytology result but still
suspected of having cancer sometimes undergo potentially
unnecessary invasive procedures. Cancer patients with no malignant
involvement of the pleura can also develop exudates (paramalignant
PEs), further confounding a cancer diagnosis. Sensitive assays that
could quickly guide patients with a cancer-related PE toward
the invasive procedures that ultimately diagnose the cancer type
and lead to early treatment commencement are favorably seen in
the clinic.
Cytokeratin (CK) markers have been used in pathological
examinations with immunohistochemistry for cancer classification
for over 30 years [6,7]. CKs are epithelial cytoskeletal proteins whose
expression pattern differs between epithelial tissues and their
developmental stages but is maintained when a malignant
transformation occurs which is helpful in tumor differentiation
[8,9]. In lung cancer, profiles of CK-5/6, CK-7, CK-10/13, CK-14,
CK-17, and CK-18 enable discrimination between SCC and ADC,
and ADC and mesothelioma [6,7,10]. Additionally, CKs provide
prognostic information and enable therapy monitoring (e.g., M30
and CYFRA 21-1 ELISAs which measure caspase-cleaved CK-18
and CK-19, respectively) [11,12]. Furthermore, one of only a few
FDA-approved protein tumor marker tests identifies circulating
tumor cells of epithelial origin in blood using antibodies against
CK-8, -18, and -19 [13]. Despite antibody-based tests being widely
used with a reliable level of analytical sensitivity, cross-reactivity and
poorly defined target issues have recently led to controversies and
questions as to their specificity [14]. This includes cancer-related CK
assays such as CYFRA 21-1 and CK-8/18 immunohistochemistry
[15,16]. Antibody-based tests, like ELISA, also do not easily
multiplex and can suffer from phenomena which underreport
high-target samples [13]. The targeted mass spectrometry (MS)–
based method, multiple reaction monitoring (MRM) with
stable-isotope-labeled standard (SIS) peptides, which is characterized
by higher analytical specificity, high precision, and the possibility of
measuring numerous proteins within a single rapid analysis, could
improve assay performance. These advantages have made this
method ideal for biomarker assessment and validation; it has seen an
increase in use in clinical proteomics and has been deemed key for
bridging biomedical discovery and clinical implementation as
expressed in the 2012 Nature Methods “Method of the Year” article
[17].
A few MS-based studies have been conducted to characterize PE
proteomes and to identify potential protein biomarkers of lung cancer
[4,18–25]. Two studies are worth mentioning as they verified a larger
group of potential biomarkers thru MRM use or assessed the results
on a large patient set [26,27]. Using marker panels, they obtained
diagnostically acceptable areas under the curve (AUC: 0.90-0.95) for
differentiating malignant (ADC/NSCLC) from control PEs [tuber-
culosis (TB) and pneumonia]. However, paramalignant PEs were
included in the control group or excluded. Similarly, studies have
shown promise in determining malignant PEs using ELISAs for
tumor markers common in clinical use, with an individual marker
specificity and sensitivity ranging between 85% and 96% and
between 25% and 55%, respectively [28]. A combination of four
such markers showed an improvement over cytology [29], revealingthat such less invasive testing may aid to select cytology-negative
patients which require further invasive procedures.
In this work, we devised a simple precipitation-based CK
enrichment method that allows the detection of low quantities of
CKs in PE and determined peptide-specific MS parameters for their
precise, specific, and sensitive multiplexed quantitation by MRM.
Using these targeted assays for 33 different CK proteins, including
some previously not associated with cancer, we screened a broad set of
121 PEs. We show which CKs are detectable and that levels of 10
CKs are related to PE etiology. For the first time, we reveal that
simple-epithelial CKs are at significantly higher levels in
cancer-related PEs and show that our method, while requiring less
invasive sampling, can significantly identify cancer-related PEs in
clinical samples and thus could shorten PE diagnosis time in the future.
Material and Methods
Clinical PE Specimens
The study was approved by the Bioethical Committee at the
Regional Medical Chamber in Warsaw (KB/928/14). PE samples
were obtained during thoracentesis and classified at the Mazovian
Center of Pulmonary Disease and Tuberculosis Treatment. A written
informed consent was obtained from each patient. Samples were
deidentified and coded for the proteomic analyses and were handled
according to Biosafety Level 2 practices. This is a preliminary study to
show if and what CKs are present in PEs related to cancer, and
therefore a predetermined sample size was not calculated as we were
analyzing all samples accessible. Thus, we were working with a real
representation of PEs in a clinical setting, including those that could
not be diagnosed. We collected 121 PEs over a 21-month period.
Forty-two PEs were from patients with a diagnosed form of cancer
(cancer PEs), 47 were from patients with non–cancer-related diseases
(benign PEs), and the etiology of 32 PEs could not be initially
established (Table 1). Within the cancer PEs, 35 were from patients
with lung cancer [28 NSCLC (15 ADC and 10 SCC), 7 SCLC] and
7 were from patients with other forms of cancer (2 pleural
mesotheliomas, 1 prostate cancer, 1 breast cancer, 1 ovarian cancer,
1 nipple cancer, and 1 cancer of unknown origin). Out of the cancer
PEs, five (12%) had positive cytology results, and additional
videothoracoscopy done on select patients increased this sum to
eight (19%) confirmed malignant PEs. The benign PE group
included 24 pleural empyema PEs (an advanced stage of a bacterial
infection, usually the complication of bacterial pneumonia), 6 TB
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liver cirrhosis (1); 8 were not further subtyped], and 3 posttraumatic
PEs. For data analysis, the cancer PE and benign PE groups were
divided into subgroups: lung-cancer PEs (n = 35), other-cancer PEs
(n = 7), bacterial-infection PEs (empyema and TB, n = 30), and
control PEs (transudate and posttraumatic PEs, n = 17).
PEs were collected into tubes with the anticoagulant EDTA
dipotassium salt dihydrate (Sigma-Aldrich, St. Louis, MO) (final
concentration, 4.5 mM) and were stored on ice for a maximum of 2
hours before processing. PEs were centrifuged at 2000 ×g for 10
minutes at 4°C to remove cellular debris. The PEs were centrifuged
again at 15,000 ×g for 10 minutes at 4°C, and the supernatants were
stored at −80°C until analysis. Total protein concentration was
determined using the bicinchoninic acid (Thermo Fisher Scientific,
Rockford, IL, USA) assay according to the manufacturer’s instructions
for the microplate plate format.
Nano-LC-MRM-MS Assay Development, Optimization,
and Analysis
Peptide selection for MRM analysis was performed according to
the criteria described previously by manual selection and the aid of the
PeptidePicker software [30]. In brief, chosen proteotypic peptides
met the following conditions: sequence uniqueness in the human
proteome; numerous observations in spectral libraries; length not
exceeding 20 amino acids; and, if possible, not containing easily
chemically modifiable residues or sequences prone to modifications.
Peptides were excluded when they had low digestion efficiency, a high
frequency of single-nucleotide polymorphisms, known posttranslational
modifications (PTMs), or biological features affecting theirmeasurement
accuracy. The selected peptide sequences were synthesized as stable
isotope–labeled standard peptides using isotopically labeled amino acids
on theC-terminus: Arg 13C6;
15N4 (98% isotopic enrichment) or Lys
13C6;
15N2 (98% isotopic enrichment) by JPT Peptide Technologies GmbH
(Berlin, Germany) as SpikeTides_L.
MRM analysis was performed as described previously with minor
modifications [31]. Briefly, a Waters Xevo TQ MS (Waters, Milford,
MA) coupled to a Waters nanoAcquity UPLC was used with peptides
loaded onto a trap column and separated using a 60-minute LC run,
with a gradient of acetonitrile changing from 1% to 10% from 0 to 10
minutes and from 10% to 50% from 10 to 40 minutes. Modified MS
parameters included a capillary voltage of 3.5 kV and NanoFlow gas
set at 2.0 bar.
To generate the highest ion signal, the optimization of peptide- and
fragment-specific MRM settings was performed as previously
described using SIS peptides [31]. In brief, the optimal precursor
charge and optimal cone voltage were determined. Best b- and
y-series fragment ions with their optimal collision energy voltages
were selected. Five to three interference-free optimized transitions
generating the highest signals were chosen. For vimentin, a standard
MRM analysis without SIS was performed using nine transitions with
calculated cone and collision energy voltages. Our analytical method
targeted 37 proteins with 115 peptides in three 60-minute LC-MRM
analyses per sample.
For MRM analysis with SIS peptides, the quantity of the
endogenous peptide is reported as the peak area ratio which is the
sum of the peak areas of all transitions for the endogenous peptide
divided by the sum of the peak areas of transitions of its heavy
standard. Equivalent SIS peptide amounts added to all samples
enabled normalization of intensity data between samples in terms ofMS signal fluctuations and postdigestion sample processing differ-
ences. For the analysis of vimentin, the sum of the peak areas of nine
transitions for the endogenous peptide was presented as the relative amount.
Signals for each sample were manually inspected to ensure correct peak
detection, accurate integration, and interference-free transitions. MRM
methods and data analyses were performed in Skyline (Ver. 3.5) [32].
Precipitation-Based CK Enrichment Method
A pooled sample of PEs, representative of the study population,
was used to establish the optimal buffer pH for increased CK
precipitation and to test the assay reproducibility. Ten different pH
levels in a 3.7-M potassium chloride (KCl; Carl Roth GmbH,
Karlsruhe, Germany) solution were tested: from pH 3.9 to 5.7,
buffered using citrate; for pH 7.5 and 8.0, buffered using 0.1 M
HEPES (Carl Roth). Citrate buffers (Carl Roth) had a final
concentration of citric acid ranging from 7.4 to 50 mM and of
trisodium citrate ranging from 42.6 to 85.2 mM. Each pH level was
analyzed in triplicate. Three replicates were analyzed for the intraday
reproducibility test, and five sample precipitations were performed on
5 different days using independent sets of reagents to establish the
interday reproducibility.
PE Sample Analysis with CK Enrichment and MRM
To limit epidermal keratin contamination from dust, PE samples
prior to trypsin digestion were handled in a HEPA-filter-laminar
safety cabinet and prepared using filtered tips and ultrapure reagents
(Sigma-Aldrich). Sample preparation and MRM analyses were
randomized. After defrosting, PEs were centrifuged at 15,000 ×g
for 5 minutes at 4°C. The supernatants were diluted with 10 mM
ammonium bicarbonate (AmmBic, Sigma-Aldrich) to a final volume of
500 μl and a final protein concentration of 15 mg/ml. Samples were
precipitated by adding 500 μl of 3.7 M KCl in citrate buffer, pH 5.1
(19.4 mM citric acid, 73.1 mM trisodium citrate), and incubating
overnight at 5°C and then pelleted by centrifugation at 14,000 ×g for 10
minutes at 4°C. Pellets were resuspended in 40μl of 8Murea (Carl Roth)
in 25 mM AmmBic and sonicated for 5 minutes. To inhibit protein
carbamylation, 60 μl of 100 mM AmmBic was added. Samples were
reduced with 5 μl of 50 mM tris(2-carboxyethyl)phosphine (in 100 mM
AmmBic, Sigma-Aldrich) for 30 minutes at 60°C and alkylated with 5 μl
of 100mM iodoacetamide (in 100 mMAmmBic, Sigma-Aldrich) for 30
minutes at 37°C. The alkylation reagent was quenched by addition of 5μl
of 100 mM DTT (in 100 mM AmmBic, Carl Roth) for 30 minutes at
37°C. Finally, 224μl of 100mMAmmBicwas added to decrease the final
urea concentration to 0.94M, and proteins were digested with 1.7μg (20
μl) of sequencing-grade trypsin (Promega, Fitchburg,WI) for 16 hours at
37°C. To quench the digestion, samples were acidified with 0.1% formic
acid (FA) to 1 ml, and a mixture of SIS peptides was added to give an
amount of individual SIS ranging roughly from 8 to 480 fmol/μg for the
SIS to be 10-fold above the average endogenous peptide concentration.
Samples were desalted using Oasis HLB 1-ml (10 mg) cartridges
(Waters). Samples were loaded, washed twice with 1.0 ml of water, and
eluted in 200μl of 50% acetonitrile, 0.1% FA. Fractions were evaporated
to dryness using a SpeedVac (Labconco) and resuspended in 28 μl of
0.1% FA, and 3.8 μl was injected for nano-LC-MS-MRM analysis.
Blanks (0.1% FA) were run between every sample.
ELISA Analysis of PEs for CK-18
To determine the CK-18 protein concentration in a set of PE
samples, we used the M65 ELISA (Peviva, Stockholm, Sweden)
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in duplicate. PE samples with high levels of CK-18 were 60 times
diluted, while the rest were diluted 10 times in Standard A as
recommended by the manufacturer.
Statistical Analysis
The data were processed using SPSS Statistics (Ver. 22.0; IBM
Corp., Armonk, NY). The nonparametric Mann-Whitney U test was
performed for the protein level comparisons. Linear regression and a
Pearson correlation analysis were used to compare the MRM and
ELISA results. Hierarchical clustering of the MRM data was
performed using the heatmap tool "heatmap.2" of the gplots package
of the statistical environment R: A Language and Environment for
Statistical Computing using the complete clustering and Euclidean
distance methods [33]. Receiver operating characteristic (ROC)
curves were performed in SPSS. The true-positive rate (sensitivity)
was plotted against the false-positive rate (FPR) (1 − specificity), and
the AUC values are reported with the 95% confidence interval (CI) as
an estimate of diagnostic usefulness. Box-plots illustrating relative
protein abundances were prepared in R version 3.2.2.
Random Forest Classifiers
Classification tasks were performed using a random forest
algorithm implemented in Scikit-learn package, a machine learning
algorithm in Python [34]. All classification performance measures
(area under ROC curve, true- and false-positive ratios) were estimated
using a 10-fold cross-validation procedure. Missing values were
replaced using median imputation. To estimate adequate forest size,
we observed how doubling the number of trees affects the
performance of classifiers, starting with a size of 10. Increasing the
size above 40 did not result in noticeable improvement in AUC
values; therefore, we opted for a simpler model with 40 trees.
Classifiers based only on geometric mean values of proteins were
trained on a selected set of top five features according to information
gain measure. However, when training on both individual peptide
values and protein geometric means, to avoid selection of highly
redundant feature sets, e.g., including geometric mean and multiple
individual peptide features from one CK, we switched to greedy
forward feature selection. For the classification of the independent PE
sample set, the value reported as score is the fraction of trees that
assigned a sample to a given group.Results
MRM Assay and CK Enrichment Method Development
To screen the PEs for the presence of CKs, we targeted all the CKs
expressed in simple epithelia, stratified squamous epithelia, suprabasal
cells, and selected structural CKs [7,8]. Specific MRM assays were
developed to measure the level of 33 CKs through unique peptides.
These included the CK-1, -1B, -2e, -2P, -3 to -6, -6A, -6B, -7 to -10,
-12 to -20, -23, -24, -26 to -28, -39, -40, and -78 to -80
(Supplementary Table S-1). Seventeen of these are associated with
some form of cancer, and 12 have been linked with lung cancer [7–9].
Multiple peptides were targeted per protein (90% of proteins with 3
or more peptides), culminating in a set of 102 peptides for which
pairing SIS peptides were generated. These standards increased the
analytical assay specificity by verifying the presence of endogenous
peptides through coelution, and selection of interference-free MRM
transitions. They also allowed to obtain accurate relative abundanceinformation for each peptide and to normalize the sample set.
Peptide-specific, optimal MRM-MS parameters were empirically
determined to improve assay sensitivity (Supplementary Table S-2) as
this was shown to increase the peptide signal by an average of 11-fold
[35]. Our MRM method also assessed the levels of serum albumin,
transferrin, actin, and vimentin using 13 peptides (Supplementary
Tables S-1 and S-2). The first two proteins were included to show
patient variation in the PE’s plasma content. Actin was included as a
possible indicator of cell damage, occurring either during sampling or
from the disease state, and vimentin was included due to links with
lung cancer progression [36].
As initial attempts of PE analysis using standardmethods revealedweak
signal intensities for only a few CKs, we resorted to developing an
enrichment method for CKs based on a salting-out effect by a
high-concentration KCl buffer, which was previously used to enrich for
intermediate filament proteins through their selective precipitation
[37,38]. Our method consisted of taking an equivalent amount of total
protein from each PE sample and adding a buffered KCl-saturated
solution. The resolubilized precipitate was subjected to tryptic digestion
and MRM-MS analysis. Because proteins precipitate preferentially
around their pI point, we tested 10 pH levels covering the entire range
of pI points for the acidic (type I) and basic (type II) CKs [38]. The
precipitation method significantly improved the detectability of many
CKs (15- to 200-fold signal increase) compared with direct PE analysis
approaches, and we observed the important cancer-related CK-7, -8, -18,
and -19. The buffer at pH 5.1 resulted in roughly a two-fold enrichment
for these CKs as compared with pH 4.9 and 5.3 (Figure 1A). Above pH
5.3, no practically quantifiable precipitate was obtained, and at pH below
4.5, nonspecific protein aggregation was observed without CK
enrichment. CK-1, CK-2e, CK-9, and CK-10 were more enriched in
the pH 5.3 buffer (Supplementary Figure S-1A). However, because these
are less often associated with cancer and, in MS analysis, sometimes
originate from dust contamination, we selected the pH 5.1 buffer as the
best one for the cancer-related CKs and used it in further analyses.
Vimentin, also an intermediate filament protein, was enriched in the pH
5.1 buffer, whereas actinwas highest in the pH5.3 buffer (Supplementary
Figure S-1A). We additionally determined the optimal trypsin amount
used in the digestion and the optimal on-column sample loading amount
for maximal signal intensity (data not shown).
To prove that a precipitation step is feasible in an analytical
technique that requires high precision, we tested the method
reproducibility. The intra- and interday precision was assessed using
replicates of a pooled PE sample for the MRM-MS measurement of
peptides for the important cancer-related CK-7, -8, -18, and -19 and
for vimentin and actin, which were later discovered to be relevant
markers. The intraday reproducibility test (Figure 1B) showed that
89% of the peptides had a coefficient of variation (CV) below 20%
and that the results were more peptide than protein dependent. We
also performed a more rigorous interday reproducibility test where the
sample was processed on 5 different days using an independent set of
reagents. Again, 89% of the peptides had a clinically acceptable CV
below 20%, although a higher proportion of peptides fell into the
10% to 20% CV range. We observed that the keratinizing epidermis
CK-1, -2e, -9, and -10 associated with dust contamination had
interday %CVs ranging over 40%, although in this pooled sample
they were observed with a low signal intensity which in MRM analysis
can contribute to low reproducibility (Supplementary Figure S-1B).
We therefore decided to keep these CKs in the MRM panel taking
dust-free precautions.
Figure 1. CK enrichment method development. (A) Optimization of pH
of the CK precipitation buffer indicating relative CK protein levels per
equivalent amount of total protein precipitated by the KCl buffer at
different pH levels. Performed in triplicate. Errors bars are standard error
of the mean (SEM). (B) The intra- and interday reproducibility
assessment of the CK enrichment method as shown for multiple
peptides of CK-7, -8, -18, and -19, and vimentin and actin. Three
replicates were analyzed for the intraday test, and five replicates on 5
different days were performed for the interday test. (C) Comparison of
CK-18 protein levels in 20 PE samples as measured by MRM and the
CK-18 ELISA. Line indicates a linear regression with 95% CI (r= 0.97).
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quantitation method to a protein-based measurement given by
ELISA. Because established ELISAs for all detected CKs do not exist,
we compared our method to the most relevant CK-18 ELISA (M65),
commonly used in cancer research [39]. Twenty individual PE
samples from a variety of diagnosed cases, spanning a wide
concentration range of CK-18, were measured using both methods.
The results were expressed in ng/ml from the ELISA reading and as a
relative amount per PE volume for the MRM measurement
(Figure 1C). A reasonable correlation was observed for the two
methods with a linear correlation coefficient (r) of 0.97. The methods
agree well at the highest concentrations of CK-18 (8-10 μg/ml) and
less in the midrange levels (0.8-4 μg/ml) where the ELISA had slightly
higher levels. Both methods were in good agreement for very low
levels of CK-18 (~70 to 360 ng/ml). This comparison revealed that
our method had a lowest level of detection (LOD; MRM signal to
noise ratio N10:1 and N8000 counts endogenous signal) of around
250 ng/ml for the CK-18 protein.
The above results show that our developed analytical method,
composed of the CK enrichment step, protein digestion, and the
targeted MRM-MS analysis with SIS peptides, can be used for the
precise relative measurement of specific CK levels in PE samples.
General Results of the MRM Analysis of 121 PEs
The sample total protein concentration within the PE set varied
marginally [mean of 42 ± 9.6 (SD) mg/ml]; however, due to the
transudate and exudate character of the PE, our analysis was carried
out with normalization on a per total protein content basis. Protein
levels were measured with up to four peptides taking the geometric
mean of their levels normalized to SIS peptide levels. CK-6 could be
measured using peptides specific for isoforms 6A and 6B or measuring
all three isoforms (CK-6A, -6B, -6C) together (CK-6). An N-terminal
peptide of CK-19 (CK-19-Nterm, amino acids 25-32) was observed to
have a different level pattern across the sample set compared with the
other three peptides from CK-19 and was treated separately in the data
analysis. Analysis of the 121 PEs revealed the presence of 16 CKs, many
of which have connections to cancer (14CKs) and lung cancer (10 CKs,
Figure 2). We detected CK-1, -2e, -4 to -10, -14 to -16, and -18 to -20
across the PE sample set (Figure 2). CK-4, CK-6A, and CK-20 were
only detected in a few samples, and CK-6A, CK-14 to CK-16, and
CK-20 were detected with low-intensity signals.
Serum albumin and transferrin had a small abundance variability across
the PE samples after the CK enrichment as well as in the neat PE sample
analysis (CVs 23% and 39%, respectively). This was in contrast to the
CKs, actin, and vimentin (CV from 77% to 584%) whose measured
levels spanned a wide range across the sample set (e.g., 400-fold difference
between highest expression and LOD sample for CK-18) (Figure 2).
Interestingly, CK-8,CK-18, andCK-19,which are often coexpressed and
pair together, also clustered together when the data set was hierarchically
clustered. This also occurred for vimentin and actin, which showed an
elevated presence in the empyema samples. A trend could also be observed
on the clustered data for CK-8, -18, -19, -19-Nterm, -6, and -7, where an
elevated level was nearly exclusively associated with cancer PEs.
Differences in Protein Levels between Cancer and Benign
PE Groups
A comparison of all cancer PEs (n = 42) to all benign PEs (n = 47)
revealed a statistically significant difference in the levels of CK-6, -7,
-8, -18, -19, and -19-Nterm (Figure 3) and in the levels of actin and
Figure 2. Heatmap display and hierarchical clustering of the MRM data of observed CKs for all analyzed PE samples. Yellow indicates a
higher abundance level. Displayed data are log transformed. The abundance is expressed on a relative scale for each protein/peptide, and
therefore, intensities cannot be compared between targets. CKs marked with an asterisk have previously been associated with lung
cancer. Individual samples are indicated by number and the type of PE as described in the text. Number and question mark denotes
nondiagnosed PEs. NA indicates where MRM data could not be acquired.
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with CK-7 and the CK-19-Nterm fragment being the most significant.
ROC curves generated based on CK-7 and CK-19-Nterm showed
diagnostically useful AUCs of 0.75 (95% CI = 0.65-0.85) and 0.83
(95% CI = 0.74-0.91), respectively (Figure 4A). Simple-epithelial
CK-7, CK-8, CK-18, and CK-19 were at high levels in many cancer
PEs in contrast to the stratified-epithelial CK-6 which was also lesssignificant. Many cancer PEs also had these CKs at baseline levels.
Interestingly, the highest CK level samples did not correlate with the
few verified malignant PEs (19% of the cancer PEs), which actually had
low to mid levels of CKs.
Actin and vimentin levels were significantly higher in the benign
PE group and the bacterial-infection PE group as revealed in a
four-group comparison (Figures 4B and 5A). More specifically, actin
Figure 3. Significant differences in CK levels between benign PEs (n=47) and cancer PEs (n=42). Box-plots indicate themedian and quartiles,
with whiskers indicating the 1.5 interquartile range. Statistical significance is indicated using the Mann-Whitney U test, **P ≤ .01, *P b .05.
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TB-PE group where three of six PEs had high levels (Supplementary
Figure S-2). These proteins emphasized the empyema-PE group from
other groups more than any other tested protein/peptide. The control-PE
group had the lowest level of actin and vimentin out of all groups. TheFigure 4. ROC curves showing diagnostic efficacy of significant targe
cancer PEs (n = 42) and benign PEs (n = 47). (B) ROC curves for
bacterial-infection PEs (n = 30) and all other PEs (n = 59). AUCs aretwo proteins could distinguish the bacterial-infection PE group from the
other samples with an AUC of 0.88 (95% CI = 0.80-0.97) for actin and
with an AUC of 0.86 (95% CI = 0.77-0.96) for vimentin (Figure 4B).
Comparing lung-cancer PEs and other-cancer PEs to the control
PEs (transudates and posttraumatic PEs) shows that it is not just thets. (A) ROC curves for CKs whose levels significantly differ between
actin and vimentin whose levels significantly differ between the
indicated for each target.
406 Profiles in Cancer-Related Pleural Effusions Domanski et al. Neoplasia Vol. 18, No. 7, 2016overabundance of the bacterial-infection PEs that causes a significant
difference in CK levels. Similarly, CK-7, CK-8, CK-18, CK-19, and
CK-19-Nterm are at significantly higher levels in the lung-cancer PEs
compared with the control PEs (Figure 5B). This difference is
observed in spite of generally lower total protein concentrations in
transudates within the control PE group (i.e., higher PE volume
analyzed). CK-7 and CK-19-Nterm again showed the highest
significance. Their amounts were also significantly lower in the
bacterial-infection PEs. In this comparison, CK-6 was significantly
higher only in the lung-cancer PEs when compared with theFigure 5. Significant differences in protein/peptide levels between lun
PEs (empyema and TB, n= 30), and control PEs (posttraumatic and tr
(B) Comparison of CK levels. Box-plots indicate the median and quar
significance is indicated using the Mann-Whitney U test, **P ≤ .01,bacterial-infection PEs. The other-cancer PE (nonlung malignancies)
group, composed of only seven cases, could not be distinguished from
the lung-cancer PEs. However, CK-7 with CK-19-Nterm and CK-8
with CK-19-Nterm were significantly higher in the other-cancer PEs
compared with the bacterial-infection PEs and the control PEs,
respectively. In summary, the simple-epithelial CKs show an elevated
level in the lung-cancer and other-nonlung-malignancy PEs as
compared with the benign PEs irrespective of whether they are
compared with the predominant transudates or the bacterial infection
exudates together or separately.g-cancer PEs (n = 35), other-cancer PEs (n = 7), bacterial-infection
ansudate PEs, n= 17). (A) Comparison of actin and vimentin levels.
tiles, with whiskers indicating the 1.5 interquartile range. Statistical
*P b .05.
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Analyzing the data with all PE subtypes separated provides
additional information on the CK profiles (Supplementary Figure S-3
and Table S-3). This revealed that CK-7 and CK-19-Nterm most
often—and sometimes also CK-8, CK-18, and CK-19—were higher
in the ADC, NSCLC, and other-cancer PEs compared with the TB,
empyema, and control PEs. SCLC and SCC did not have this level of
significant differences, showing lower levels of these CKs. Samples
denoted NSCLC could not be clinically subclassified into ADC or
SCC but were thought by the clinicians to be more likely an advanced
form of ADC (personal communication). Although we only analyzed
three such NSCLC PEs, these were often very high for the mentioned
CKs. Interestingly, a comparison within lung cancer subtypes
revealed significant differences in the levels of CK-2e, -7, -9, -10,
and -19 between SCLC, ADC, and SCC (Figure 6). ADC had higher
levels of CK-7 compared with SCLC and SCC and of CK-19
compared with SCC. In contrast, SCC had higher levels of CK-2e, -9,
and -10 compared with ADC. We also observed very high abundance
of CKs-4, -6, and -6A in some NSCLC and mesothelioma PEs and in
a prostate-cancer PE.
A Classifier for PE Subtyping
The above data encouraged us to build a classifier tool that could
combine the results of individual protein/peptide targets and with a
multiplexed panel classify PE samples into their appropriate categories
with increased power. Due to the nature of the eight PE groups, we
first decided to use a nested dichotomy approach, building a set of
binary classifiers and recursively splitting a larger group into twoFigure 6. Significant differences in CK levels between lung cancer su
indicate the median and quartiles, with whiskers indicating the 1.5
Mann-Whitney U test, **P ≤ .01, *P b .05.smaller subgroups (Figure 7). Although this is not necessary as
random forest classifiers can handle multiclass problems directly, we
believe that it is useful to look at the performance of each classifier
individually. The classifiers were built on the geometric mean levels
for all CKs, actin, and vimentin; the level of the CK-19-Nterm
peptide; and the total protein concentration. The first classifier was
able to discriminate the bacterial-infection PEs from all other PEs
with an AUC of 0.92 ± 0.02 (Figure 7), with the top five contributing
factors being (in order of weight) actin, vimentin, CK-19-Nterm,
CK-7, and CK-19. The next classifier took the noninfected samples
and split them into cancer PEs or control PEs with an AUC of 0.77 ±
0.04 based on the total protein concentration and the levels of CK-8,
-19, and -18 and actin. Beyond this division level, the classifiers
failed to provide high-significance subtyping, except for the
moderate ability to differentiate the two PE groups of SCC and
ADC from each other with an AUC of 0.65 ± 0.05 based on the top
five CKs being CK-9, -7, -2e, -6A, and -5.
The above results show that the most practical aspect of a classifier will
be the differentiation of the cancer PEs versus benign PEs. For increased
accuracy, a new two-group classifier was built with the above data plus
additionally submitting all peptide-level values as independent factors as
individual peptides might have their own behavior independent of the
geometric mean protein level (e.g., CK-19-Nterm). The resulting
classifier had an AUC for classifying cancer PEs from benign PEs of 0.87
(Figure 8A). At an FPR of 21%, this test has a sensitivity of 81% at
correctly identifying patients with a cancer PE (Figure 8B). At an FPR set
at 9%, for example, to exclude more noncancer patients being sent for
invasive procedures, the classifier is predicted to correctly classify 50% ofbtypes: SCLC (n = 7), ADC (n = 15), and SCC (n = 10). Box-plots
interquartile range. Statistical significance is indicated using the
Figure 7. Performance of individual classifiers for PE subtyping.
Classification tasks were performed using a random forest
algorithm. Classification performance measure (AUC plus/minus
error) was estimated using a 10-fold cross-validation procedure.
Bacterial-infection PEs: empyema and TB. Control PEs: posttrau-
matic and transudate PEs. Cancer PEs: all lung- and other-cancer
PEs. Best 5 indicates the top five contributing features used by the
classifiers for the indicated separation.
Figure 8. Performance of the two-group classifier for the cancer PE
versus benign PE classification. (A) Classifier AUC for classifying
cancer PEs from benign PEs and the top seven contributing features
used for this separation. (B) ROC curve of the two-group classifier.
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that were used for this separation in order of weight are CK-7_FET,
CK-6_ADT, vimentin_ILL, protein concentration, CK-4_NLE,
CK-19_geo, and vimentin_ISL [protein name_three amino acids of
peptide or geometric mean (geo) of all peptides used].
Analysis of Undiagnosed PEs Using the Two-Group Classifier
Using the two-group classifier, we analyzed data from the 32 PEs that
could not be diagnosed at the initial clinical assessment. The classifier
results for these independent samples could be compared for some PEs
where more clinical data were obtained to derive a later diagnosis,
whereas others remained with an unresolved etiology (Table 2). The
classifier indicated one high-scoring sample (score = 1.0) with an FPR of
5% and four samples with scores ranging from 0.75 to 0.80 but with an
FPR of 10% for being cancer PEs. For the highest-scoring sample, a
later videothoracoscopy examination confirmed a malignant NSCLC
case. For PEs with the higher FPR of 10%, one patient had a later
diagnosis revealing pleurisy (inflammation of the pleura); another
patient was diagnosed with bacterial pneumonia; and for the remaining
two patients, there was no definite diagnosis. One patient (#91) with a
score of 0.27 was later diagnosed with NSCLC based on a computed
tomographic scan but with a paramalignant PE. All PE samples
tested had negative cytology results, and the remainder of the patients
(scores ≤0.7) had no evidence of cancer, with 10 remaining with an
undetermined etiology of PE.Discussion
For the first time, we report on the development of targeted MS-based
assays to simultaneously quantify a comprehensive set of 33 CKs and
screen for these in a broad set of PEs. We reveal the detectable CKs
and show that 10 CK abundance levels relate to PE etiology. To the
best of our knowledge, this work is also the first to show the detection
and quantitation of the important cancer-related simple-epithelial
CKs (CK-7, -8, -18, and -19) as a multiplexed panel in PE. No
MS-based or immunobased methods have demonstrated this before.
Furthermore, no previous work has shown an increase of these CKs in
the cancer PEs despite such evidence existing for solid lung tumor
tissues. We believe that this is due to our CK enrichment method and
the multiplexing capability of MRM analysis.
Initially, we analyzed PEs using in-solution digestion methods used
for plasma analysis [40] because PEs consist two thirds of plasma
proteins [19]. These targeted approaches, additional global-MS
analyses, and alternate methods for trypsin-resistant proteins revealed
weak signal intensities for only a few CKs, indicating that CK levels
are low among the total protein PE content even in highly positive
samples (data not shown). Published PE proteomic investigations,
despite applying methodologies to reveal low-abundance biomarkers,
largely identified only the high-abundance and potentially contam-
inating structural- and stratified-epithelial CKs [19,20,26,27,41].
Our CK enrichment method improved the assay sensitivity with a
signal increase of up to 200-fold, which is comparable to
antibody-based enrichment methods but without the large reagent
cost. Furthermore, the enrichment works on a large population of
CKs, i.e., versus requiring an antibody for each protein, and the
Table 2. Classification Results of the Two-Group (Benign PE Versus Cancer PE) Classifier Performed on an Independent PE Sample Set
Sample Score FPR = 5% FPR = 10% PE Type Videothoracoscopy Cytology of PE Sediment Etiology of PE
62 1 + Exudate Cancer revealed Negative NSCLC (malignant)
9 0.8 + Exudate NP Negative Pleurisy
15 0.77 + Exudate NP Negative Bacterial pneumonia
106 0.77 + Exudate NP Negative Unknown (suspicion of lupus)
75 0.75 + Exudate NP Negative Unknown (diaphragmatic hernia)
69 0.7 Exudate NP Negative Pleurisy
48 0.67 Exudate No evidence of cancer Negative Unknown
77 0.62 Exudate No evidence of cancer Negative Unknown
16 0.6 Exudate NP Negative Bacterial pneumonia
37 0.57 Exudate NP Negative Unknown (heart and renal failure)
60 0.52 Exudate NP Negative Pleurisy
81 0.52 Exudate NP Negative Bacterial pneumonia
33 0.5 Exudate NP Negative Unknown (suspicion of leukemia)
12 0.45 Exudate NP Negative Unknown
132 0.45 Exudate No evidence of cancer Negative Unknown
53 0.42 Exudate NP Negative Bacterial pneumonia
40 0.32 Transudate NP Negative Heart and renal failure
43 0.3 Exudate NP Negative Tuberculosis
113 0.3 Exudate NP Negative Unknown (heart failure)
127 0.3 Exudate No evidence of cancer Negative Unknown (renal failure)
91 0.27 Exudate NP Negative NSCLC (paramalignant)
30 0.25 Exudate NP Negative Unknown (tumor of left kidney)
13 0.22 Exudate NP Negative Bacterial pneumonia
82 0.17 Exudate NP Negative Bacterial pneumonia
129 0.17 Exudate NP Negative Tuberculosis
115 0.15 Exudate No evidence of cancer Negative Inflammation
74 0.12 Exudate NP Negative Unknown (history of chest trauma)
105 0.1 Exudate NP Negative Bacterial pneumonia
110 0.1 Exudate NP Negative Bacterial pneumonia
121 0.07 Transudate NP Negative Liver failure and ascites
20 0.05 Exudate NP Negative Pleurisy
26 0.05 Exudate NP Negative Pleurisy
Thirty-two patient PEs whose etiology could not be determined in the initial clinical assessment were analyzed and are presented with a later obtained diagnosis for some and other clinical data. Score and
FPR are results of the classifier. NP, not performed.
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workflow.
Based on the ELISA, our method has a CK-18 LOD of 250 ng/ml,
and we expect this to be similar for other CKs as they are structurally
highly related. The CK-18 ELISA with an equally determined LOD
(at signal to noise ratio N10:1) of 44 ng/ml showed better analytical
sensitivity. However, its analytical specificity is not guaranteed, and
the test lacks the multiple levels of molecular specificity assessment
that MRM provides. A contributing interference (e.g., other CKs) in
the ELISA could cause the observed slightly higher CK-18 levels
compared with our method for the midrange samples. The lowest
sample measured by the ELISA had 73 ng/ml of CK-18, which is
below the capability of our method; however, it has been
demonstrated that newer-generation MS instruments could reach
quantitation levels even in the range of 1 to 10 ng/ml for certain
plasma proteins [42]. This could eliminate the need for CK
enrichment, making the analysis more robust due to a simpler
workflow. We plan to test this, additionally using SIS peptides
characterized by amino acid analysis to obtain precise quantitation
values defined in absolute units of ng/ml which will be more
appropriate in a clinical application allowing for reference values to be
set up and for comparisons of results across studies.
The analysis of 121 PEs revealed the presence of 16 CKs, many of
which have connections in the literature to lung cancer (CK -5 to -8, -10,
-14, -16, -18, and -19) as well as to other non-lung cancers (as for lung
cancer plus: CK-1, -4, -15, and -20) [7,9]. Some of these are used in
pathological examinations for lung cancer classification and prognosis
(CK-5/6, -7, -8/18, and -19) [7,8,11] or have been published as potentialbiomarkers in lung cancer research [43,44].DetectedCK-2e andCK-9 are
not often associated with cancer, but they can pair with the cancer-related
CK-1 andCK-10. All four are expressed in stratified epithelia and thus can
be potential dust contamination in MS analysis from the keratinizing
epidermis. Due to the indefinite reproducibility test results caused by low
signals for these CKs, we kept them in the MRM panel, taking dust-free
precautions, and in the individual patient analysis, their signals were indeed
increased in specific PEs, revealing significantly elevated levels of CK-2e,
-9, and -10 in the SCC group compared with ADC.
CK-6, CK-7, CK-8, CK-18, and CK-19 are at significantly higher
levels in cancer PEs. Still, many PEs diagnosed as cancer related had
baseline levels of these CKs. Possibly, these are below the LOD of our
method, and future instrumentation and improved methodology
could allow their measurement, increasing the power of the assay.
Nonetheless, these CKs show an elevated level in the lung-cancer and
other-cancer PEs irrespective of whether they are compared with the
predominant transudates or empyema PEs together or separately
(Figures 3 and 5), indicating that we detected cancer-specific changes
rather than what would be evoked in an advanced infection or in a
transudate PE. Some PE types had a small number of samples and
would need to be analyzed in a larger set to verify that the above CKs
are low, e.g., posttraumatic and TB PEs. Traumatic injury, however,
usually has an immediate diagnosis, and none of the six analyzed TB
PEs had elevated CK levels, on average being lower than in the
transudate or empyema PEs (Supplementary Figure S-3).
Elevated levels of the simple-epithelial CK-7, -8, -18, and -19 in
the cancer PEs are in full agreement with solid lung tumor tissue
analysis. Comparing normal lung tissue with lung ADC by 2D gel
410 Profiles in Cancer-Related Pleural Effusions Domanski et al. Neoplasia Vol. 18, No. 7, 2016electrophoresis combined with Western and MS identification,
Gharib et al. showed that the same four CKs are significantly
increased in tumors which also correlated with their increased mRNA
level [45]. Furthermore, in pathology, CK-8/18 and CK-19 are
characteristic for several lung cancer types, whereas CK-7 is specific to
ADC [7]. This indicates that our biofluid analysis is sensitive enough
to detect changes occurring in the tumor tissue itself, and supports
our strategy of devising an analytical method that can rely on less
invasive sampling procedures. Release of CKs from tumor cells can
occur during apoptosis or necrosis but also, as has been shown for
CK-19, can be an active process releasing full-length protein from
viable tumor cells, which in this case also correlated with bad
prognosis [15].
CK-8, CK-18, and CK-19 compose three cancer biomarkers often
applied in the clinical laboratory (tissue polypeptide antigen, tissue
polypeptide specific antigen, and CYFRA 21-1) [11] for treatment
monitoring and prognosis as their plasma levels indicate ongoing
tumor cell activity [46]. This suggests an alternate use for our MRM
panel yet to be evaluated.
Despite low numbers of PE samples in the lung cancer subtypes, like
for the rare SCLC, we observed differences with some consistency to
reports from lung cancer tissues. In histological typing, ADC has higher
immunostaining rates for CK-7 and CK-18, whereas SCC is higher for
CK-10/13 [10]. We observed that ADC had higher levels of CK-7
compared with SCLC and SCC and of CK-19 (highly related to CK-18)
compared with SCC. SCC compared with ADC had elevated levels of
CK-10 and additionally of CK-2e and CK-9, which are a binding partner
and a biologically related CK to CK-10, respectively. Additionally, our
classifier, although limited in its ability at differentiating the cancer
subtypes, could distinguish ADC and SCCwith amoderate AUCof 0.65
(based on CK-9, -7, -2e, -6A, and -5), making the avenue of cancer
subtype differentiation encouraging. Future analysis with larger groups of
these subtypes is a next step to verify this.
Gharib et al. observed that specific isoelectric point isoforms (likely
due to PTMs) of the simple-epithelial CKs correlated with different
clinical variables [45]. Interestingly, antibody cross-reactivity was
observed for some isoforms of CK-7 and CK-8, highlighting the issue
of inferior specificity of immunobased detection. This is especially
relevant if biomarkers are specific peptides and not whole proteins.
This might result from biological reasons as cancer-related PTMs
(e.g., phosphorylation) or proteolytic activities from elastase or
caspases (e.g., on CK-19) [11]. We observed that a specific peptide of
CK-19 (CK-19-Nterm), located in the head region commonly
involved with PTMs, behaved differently from the other CK-19
peptides. A phosphorylation site shown to modulate filament
organization is located three amino acids away from this peptide’s
trypsin cleavage site and could affect digestion efficiency [47]. This
peptide alone differentiated the benign PEs and cancer PEs with an
AUC of 0.83, which was much higher than that for the total CK-19
protein level (Figure 4A).
Bacterial-infection PEs could be excluded from our analysis as
noncancer PEs with high confidence (AUC = 0.92) using a classifier
that combines the actin and vimentin results with measurements of
CK-19-Nterm, -7, and -19. Actin has been observed to be higher in
TB and pneumonia PEs compared with malignant PEs in global
proteomic analyses but was described as a potential marker (lowered)
of malignant PEs with no connection to an infection [4,21,22]. To
the best of our knowledge, the parallel changes in vimentin levels have
also not been associated with PEs from infected individuals; rather,vimentin has been overexpressed in cancer and metastasis and
recognized as a marker for the epithelial-to-mesenchymal transition
[48]. But it has been demonstrated that macrophages, which are also
the major host harboring Mycobacterium tuberculosis, in response to
proinflammatory signaling secrete vimentin which is involved in
bacterial killing, and this could explain the elevated levels [49,50].
Our two-group classifier had a sensitivity of 81% and a specificity
of 79% for identifying cancer-related PEs (AUC = 0.87). This is a
very promising result comparable to published PE research where
sensitivity and specificity ranged between 25% and 55% and between
85% and 100% (AUC = 0.65-0.95), respectively, in identifying
malignant PEs using ELISA- or proteomic-based markers or panels
thereof [26–29]. Noteworthy is that, in these studies with high AUC
values (N0.9), classifications were performed only for PEs from
malignant cases likely to have the highest marker levels [26,27]. We
believe that our analysis is an improvement as we considered both
malignant and paramalignant PEs in the “cancer PE” group. For
comparison, our best single marker had an AUC of 0.83 compared
with that of Chen et al. whose best single marker had an AUC of 0.76
in such a grouping [26]. Our results are also on par with the
FDA-approved test (CELLSEARCH) which partly uses CK
antibodies [51] as it was used to improve on cytology assessment,
differentiating malignant from benign PEs with an AUC of 0.86 and
a sensitivity of 78% and specificity of 86% [52]. We had insufficient
clinical data to exclude paramalignant PEs, and possibly, our classifier
could score even higher in a malignant-centric approach. Comparing
our results to cytology, which was positive for only 12% of the cancer
PEs, and to videothoracoscopy, which further verified 19% of cancer
PEs as definite malignant PEs, shows that our method, e.g., at 50%
sensitivity and a 91% specificity for classifying cancer PEs, has
potential at diagnosing cancer PEs not just associated with a
metastasis to the pleura. The verified malignant PEs although scoring
high in our classifier (N0.8) and having increased levels of the
simple-epithelial CKs were exceeded in both respects by many other
cancer PEs, indicating that some malignant PEs might have also been
missed due to the high false-negative rate of cytology and because
videothoracoscopy was performed on only a few patients.
The selection of top factors for a differentiation in the two-group
classifier was made based on a “greedy forward feature selection”
method to avoid selection of markers with redundant behavior. This
explains why the CK-19-Nterm peptide with the highest significance
in the individual protein comparisons was later outperformed by
similarly acting but slightly better differentiating peptides in the
classifier. The classifier for SCC/ADC as expected from individual
protein comparisons selected CK-7, -2e, and -9 as top factors but
additionally chose CK-6A and -5, which alone showed no
significance. This highlights the power of a multiplexed target panel
and classifier tool which can use markers that individually are not
differentially abundant but grouped together can be predictive.
Analyzing data using the two-group classifier from an unrelated set
of 32 PEs, which could not be diagnosed at the time of sampling,
scored one case at 1 with an FPR of 5% for being cancer related.
Later, it was indeed confirmed to be caused by malignant NSCLC.
Four samples diagnosed later as benign had moderate scores
(0.75-0.8) but an FPR of 10%, suggesting a 5% FPR with a score
N0.8 as a cutoff for this classifier. Another NSCLC case did score only
0.27, but it had no involvement of the pleura (paramalignant PE).
This independent sample set, although limited in cancer PEs, allowed
to show that our classifier can identify an undiagnosed cancer-related
Neoplasia Vol. 18, No. 7, 2016 Profiles in Cancer-Related Pleural Effusions Domanski et al. 411PE missed by early standard clinical assessment. Thus, our analytical
workflow can potentially shorten diagnosis time and guide patients to
appropriate procedures. With refinement, in the future, such an assay
could be an additional tool among existing clinical tests performed on
patients presenting with PEs at first assessment.
Conclusions
This work integrates a collection of clinical samples and biochemical
data obtained by advanced MS techniques for increased analytical
specificity to capture a fingerprint of CK levels in the context of
specific lung diseases. For the first time, we report on the quantitation
of a wide panel of CKs in a multiplexed assay and screening a broad
set of PEs that revealed the cancer-related increase of simple-epithelial
CKs which are established tumor markers. These novel findings in
PE, obtained by a less invasive procedure, corroborate observations in
solid tumors. Using advanced statistical methods, we can significantly
classify benign PEs versus cancer PEs and hope that this analytical
workflow can be implemented into clinical applications in the future.
Such a screening, following imaging diagnostics, in many clinical
situations could precede the often difficult decision on the next steps
involving highly invasive procedures. Also encouraging is the
perspective of less invasive treatment monitoring, e.g., tumor
stabilization versus progression in the case of lung cancer, as well as
the analysis of other biofluids and epithelial cell–related cancers using
our developed CK MRM panel.
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